Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when
administered as a subcutaneous injection at the individualized maintenance dose level in an
OFF state in Parkinson's disease patients with motor response complications on levodopa
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.